KJ C2219
Alternative Names: CT-1190B; KJ-C2219Latest Information Update: 26 Aug 2026
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; Systemic lupus erythematosus; Systemic scleroderma
Most Recent Events
- 18 Aug 2026 NMPA approves IND application for KJ C2219 in Non-Hodgkin's lymphoma (Second-line therapy or greater)
- 14 Jun 2026 CARsgen plans a phase Ib trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in 2026 (Parenteral)
- 16 Jun 2025 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-experienced) in China (Injection) (NCT07031713) (CARsgen Therapeutics pipeline, June 2025)